Whalesbook
Arre, suno suno! Gland Pharma ne FY26 ke Q4 mein ekdum records tod diye. Net profit 97% bhadka ke ₹3,666.75 crore tak pahunch gaya aur revenue bhi 22.3% badh kar ₹17,427.9 crore ho gaya. EBITDA mein bhi 48% kaafi achha jump aaya aur margins 29.4% tak pahunch gaye, jo pehle 24.4% the. Company ne shareholders ko khush karne ke liye Rs 20 ka dividend bhi recommend kiya hai.
Lekin asli dhamaka toh market mein hua! Itni zabardast numbers aane ke baad bhi, Gland Pharma ka stock Friday ko 1.6% neeche gir gaya, jabki Nifty Index toh bas 0.19% hi gira tha. Iska matlab kya hai? Simple si baat hai, investors sirf current profit nahi dekh rahe, balki company ki future growth aur uska valuation bhi check kar rahe hain.
Valuation ka Chakkar Kya Hai?
Gland Pharma ki market cap lagbhag ₹30,000 se ₹31,500 crore hai. Company ka P/E ratio bhi 25.99 se 37.05 ke beech mein chal raha hai. Ab jab P/E itna high hota hai, toh market expects karti hai ki growth bhi high ho. Jab Nifty Pharma index ka P/E 37.8 hai, toh Gland Pharma ka P/E iske aas paas hi hai. Sun Pharma aur Dr. Reddy's jaise bade players ke comparison mein toh yeh average hi lagta hai. Par stock ka giraana indicate karta hai ki investors ko lagta hai ki future mein itni growth nahi milegi jitna price hai.
Sector Trends aur Pichli Performance
Past mein bhi Gland Pharma ke results par stock ne kabhi upar, toh kabhi neeche move kiya hai. Kabhi 7.41% bhaga, toh kabhi 0.89% ya 1.28% gira. Is baar bhi wahi hua. Indian pharma sector mein 7-9% growth expected hai FY2026 mein, par US market mein growth thodi slow ho rahi hai (3-5%). Yeh export-focused companies ke liye thoda challenge ho sakta hai.
Analysts Kya Keh Rahe Hain?
Bahut se analysts 'Buy' ya 'Outperform' recommend kar rahe hain aur target price ₹1,966 se ₹2,000 ke beech mein de rahe hain. Lekin kuch analysts ne target kam bhi kiye hain. Company ko apna valuation maintain karne ke liye consistent growth dikhani padegi aur US jaise markets mein competition aur pricing pressures ko manage karna hoga.